Bio-Rad Laboratories, Inc. Class A Common Stock vs Peloton Interactive Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Peloton Interactive Inc trades at $6.17 (market cap $2.67B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 3× Peloton Interactive Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Peloton Interactive Inc nearer its low. Which is the better fit depends on your goals.
| BIO | PTON | |
|---|---|---|
Market Cap | $8.04B | $2.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $9.00 |
52-Week Low | $241.71 | $3.71 |
Enterprise Value | $7.85B | $3.27B |
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Peloton (PTON) trades at $6.08, up 3.75% on the day, as technical indicators show a bullish trend with neutral oscillators. The company has achieved a significant turnaround in cash flow, with operating cash flow positive at $333 million in 2025, and is projected to return to net profitability in 2026. However, revenue continues to decline, and the stock carries a high P/E ratio of 101.25, reflecting investor optimism about future earnings despite current challenges. Recent news highlights inclusion in the S&P SmallCap 600 index and leadership changes.
The outlook for PTON hinges on sustaining profitability and reversing revenue declines. Opportunities include strong free cash flow generation and cost-cutting success, but risks involve persistent revenue shrinkage, high debt levels, and intense competition. Analyst consensus is cautiously optimistic with a $7.50 price target, suggesting potential upside if execution improves.
Trailing returns across standard periods
Latest headlines on both assets
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →